Abstract
Sjögren syndrome (SS) is one of the most common unexplained intractable autoimmune diseases occurring in middle-aged women. Patients with SS manifest progressive dryness symptoms due to insufficient salivary and lacrimal secretions. Xerostomia, defined as dry mouth, is a subjective symptom that most commonly appears in SS patients. Available causal treatment of xerostomia has been limited, and then the establishment of a causal treatment with no or less side effect is urgently needed. The effect of noninvasive low-intensity pulsed ultrasound (LIPUS) on soft tissues has received much attention for promoting effects on soft tissue healing. Thus, LIPUS may have considerable clinical potential for treatment of injured or pathological soft tissues including salivary gland. Recently, we investigated the effects of LIPUS on salivary gland cells and demonstrated that the expression of aquaporin 5 (AQP5), a water channel protein, in human salivary gland acinar cells was inhibited by TNF-α treatment, whereas it was recovered following LIPUS treatment. In addition, our in vivo study using MRL/lpr mice, the best model for SS, suggests that LIPUS treatment restored salivary gland secretion volumes in older MRL/lpr mice, thereby promoting an anti-inflammatory response and improving AQP5 dysfunction. It is concluded that LIPUS stimulation may represent a treatment strategy for inflammatory diseases of salivary glands, including xerostomia in SS.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fox RI. Sjögren’s syndrome. Lancet. 2005;366:321–31.
Daniels TE. Labial salivary gland biopsy in Sjögren’s syndrome: assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum. 1984;27:147–56.
Yamamura Y, Motegi K, Kani K, Takano H, Momota Y, Aota K, et al. TNF-α inhibits aquaporin 5 expression in human salivary gland acinar cells via suppression of histone H4 acetylation. J Cell Mol Med. 2012;16:1766–75.
Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren’s syndrome. J Immunol. 1994;152:5532–9.
Hamano H, Saito I, Haneji N, Mitsuhashi Y, Miyasaka N, Hayashi Y. Expressions of cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice. Eur J Immunol. 1993;23:2387–91.
Soliven B, Wang N. Tumor necrosis factor-α regulates nicotinic responses in mixed cultures of sympathetic neurons and nonneuronal cells. J Neurochem. 1995;64:883–94.
King LS, Yasui M. Aquaporins and disease: lessons from mice to humans. Trends Endocrinol Metab. 2002;13:355–60.
Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjögren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996;5(Suppl 1):S31–6.
Kruize AA, Hené RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52:360–4.
Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312:249–58.
Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren’s syndrome: a pilot study. Arthritis Rheum. 2001;44:2371–5.
Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren’s Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.
Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5.
Desai D, Goldbach-Mansky R, Milner JD, Rabin RL, Hull K, Pucino F, et al. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother. 2009;43:967–72.
Antoni C, Braun J. Side effects of anti TNF therapy: current knowledge. Clin Exp Rheumatol. 2002;20:S152–7.
Nagata K, Nakamura T, Fujihara S, Tanaka E. Ultrasound modulates the inflammatory response and promotes muscle regeneration in injured muscles. Ann Biomed Eng. 2013;41:1095–105.
Nakamura T, Fujihara S, Katsura T, Yamamoto K, Inubushi T, Tanimoto K, et al. Effects of low-intensity pulsed ultrasound on the expression and activity of hyaluronan synthase and hyaluronidase in IL-1β-stimulated synovial cells. Ann Biomed Eng. 2010;38:3363–70.
Nakamura T, Fujihara S, Yamamoto-Nagata K, Katsura T, Inubushi T, Tanaka E. Low-intensity pulsed ultrasound reduces the inflammatory activity of synovitis. Ann Biomed Eng. 2011;39:2964–71.
Tanaka E, Kuroda S, Horiuchi S, Tabata A, El-Bialy T. Low-intensity pulsed ultrasound in dentofacial tissue engineering. Ann Biomed Eng. 2015;43:871–86.
Takakura Y, Matsui N, Yoshiya S, Fujioka H, Muratsu H, Tsunoda M, et al. Low-intensity pulsed ultrasound enhances early healing of medial collateral ligament injuries in rats. J Ultrasound Med. 2002;21:283–8.
Sato M, Kuroda S, Mansjur KQ, Ganzorig K, Nagata K, Horiuchi S, et al. Low-intensity pulsed ultrasound rescues insufficient salivary secretion in autoimmune sialadenitis. Arthritis Res Ther. 2015;17:278.
Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–71.
Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30:383–91.
Delporte C, O’Connell BC, He X, Lancaster HE, O’Connell AC, Agre P, et al. Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci USA. 1997;94:3268–73.
Kohler PF, Winter ME. A quantitative test for xerostomia: the Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum. 1985;28:1128–32.
White SC, Casarett GW. Damage of rat thyroid by 131I and evidence against immunologic transferability. Radiat Res. 1974;57:288–99.
Yamanoi T, Aota K, Momota Y, Azuma M. Treatment with the biscoclaurine alkaloid Cepharanthin Significantly Increases Salivary Secretion in Primary Sjögren’s Syndrome Patients. J Oral Health Biosci. 2017;29:39–48.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Sato, M., Inubushi, T., Tanaka, E. (2018). Application of LIPUS to Salivary Glands. In: El-Bialy, T., Tanaka, E., Aizenbud, D. (eds) Therapeutic Ultrasound in Dentistry. Springer, Cham. https://doi.org/10.1007/978-3-319-66323-4_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-66323-4_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-66322-7
Online ISBN: 978-3-319-66323-4
eBook Packages: MedicineMedicine (R0)